MX2011004244A - Ligandos que tienen especificidad de enlace para dc-sign. - Google Patents

Ligandos que tienen especificidad de enlace para dc-sign.

Info

Publication number
MX2011004244A
MX2011004244A MX2011004244A MX2011004244A MX2011004244A MX 2011004244 A MX2011004244 A MX 2011004244A MX 2011004244 A MX2011004244 A MX 2011004244A MX 2011004244 A MX2011004244 A MX 2011004244A MX 2011004244 A MX2011004244 A MX 2011004244A
Authority
MX
Mexico
Prior art keywords
lip1
seq
sign
amino acid
sequence
Prior art date
Application number
MX2011004244A
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Maria De Wildt
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of MX2011004244A publication Critical patent/MX2011004244A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2011004244A 2008-10-21 2009-10-19 Ligandos que tienen especificidad de enlace para dc-sign. MX2011004244A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21
PCT/EP2009/063655 WO2010046337A2 (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for dc-sign

Publications (1)

Publication Number Publication Date
MX2011004244A true MX2011004244A (es) 2011-05-25

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004244A MX2011004244A (es) 2008-10-21 2009-10-19 Ligandos que tienen especificidad de enlace para dc-sign.

Country Status (16)

Country Link
US (1) US20110257373A1 (enExample)
EP (1) EP2356149A2 (enExample)
JP (1) JP2012506237A (enExample)
KR (1) KR20110071139A (enExample)
CN (1) CN102257009A (enExample)
AR (1) AR073905A1 (enExample)
AU (1) AU2009306424A1 (enExample)
BR (1) BRPI0919714A2 (enExample)
CA (1) CA2740856A1 (enExample)
EA (1) EA201100488A1 (enExample)
IL (1) IL212086A0 (enExample)
MX (1) MX2011004244A (enExample)
TW (1) TW201019962A (enExample)
UY (1) UY32189A (enExample)
WO (1) WO2010046337A2 (enExample)
ZA (1) ZA201102763B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004245A (es) * 2008-10-21 2011-09-06 Domantis Ltd Composicion para dirigirse a las celulas dendriticas.
US9481724B2 (en) * 2011-12-19 2016-11-01 The Rockefeller University hDC-sign binding peptides
WO2023028593A2 (en) * 2021-08-27 2023-03-02 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP4889493B2 (ja) * 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
JP5185624B2 (ja) * 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
JP2008533115A (ja) * 2005-03-18 2008-08-21 ドマンティス リミテッド カンジダ抗原に対する抗体
EP1966242A1 (en) * 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Limited ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
EP2077863A4 (en) * 2006-10-31 2010-10-06 Domantis Ltd intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
JP2012506237A (ja) 2012-03-15
CA2740856A1 (en) 2010-04-29
KR20110071139A (ko) 2011-06-28
UY32189A (es) 2010-05-31
EA201100488A1 (ru) 2011-12-30
ZA201102763B (en) 2012-09-26
AU2009306424A1 (en) 2010-04-29
US20110257373A1 (en) 2011-10-20
IL212086A0 (en) 2011-06-30
CN102257009A (zh) 2011-11-23
WO2010046337A3 (en) 2010-07-01
AR073905A1 (es) 2010-12-09
WO2010046337A2 (en) 2010-04-29
EP2356149A2 (en) 2011-08-17
BRPI0919714A2 (pt) 2015-12-08
TW201019962A (en) 2010-06-01

Similar Documents

Publication Publication Date Title
JP7019198B2 (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
CN109937212B (zh) B7-h3抗体、其抗原结合片段及其医药用途
RU2727914C2 (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
CN105121467A (zh) 抗cd47抗体及其使用方法
HK1247214B (zh) 一种pdl-1抗体、其药物组合物及其用途
JP2017520253A (ja) 多重特異性抗体コンストラクト
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
JP2022528230A (ja) Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
EP3559030A1 (en) Anti-il-5 antibodies
US20110257373A1 (en) Ligands that have binding specificity for dc-sign
CN110114370A (zh) 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
CA3192254A1 (en) Antibody specifically bound to glycosylated ceacam5
EP4253415A1 (en) Antibody and preparation method therefor
CN114920842B (zh) 特异性结合pv-1蛋白的抗体或其抗原结合片段及其应用
US20250223361A1 (en) Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
TW202542202A (zh) 抗體、抗原結合片段及其醫療用途
WO2024149237A1 (zh) TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用
CN117915950A (zh) 一种多特异性抗体及其用途

Legal Events

Date Code Title Description
FA Abandonment or withdrawal